Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies
Annals of the New York Academy of Sciences(2023)
摘要
Nonalcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease worldwide and a leading indication for liver transplantation in the United States. NAFLD encompasses a heterogeneous clinicopathologic spectrum, ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis, and progressive fibrosis, which can lead to end-stage liver disease including cirrhosis and hepatocellular cancer. Predictive models suggest that over 100 million adults in the United States will have NAFLD by 2030, representing over a third of the population. In this manuscript, we provide an overview of NAFLD risk factors, natural history (including hepatic and extra-hepatic outcomes), diagnosis, and current management strategies.
更多查看译文
关键词
clinical trials,fibrosis,metabolic dysfunction-associated fatty liver disease,nonalcoholic fatty liver disease,nonalcoholic steatohepatitis,weight loss
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要